MOU with Swansea University (access to Supercomputer “Blue C”)

Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it has signed a Memorandum of Understanding ('MOU') with the Institute of Life Science of Swansea University, which will provide mutual benefits. Under the terms of the MOU, Physiomics will have access to the Supercomputer “Blue C”, one of the most powerful computers in the world dedicated to Life Science and is the result of a collaboration between the University, the Welsh Assembly Government and computer giant IBM. This will reinforce Physiomics’ modelling framework and help to address the ever increasing computing requirements in the field of System Biology.

Physiomics Collaboration Update – Cancer Cell Death Model Developed

ValiRx, the cancer therapeutics company, today announces that Phase 1 of its collaboration with Physiomics plc, the European systems biology simulation company, has been completed. Under the collaboration, originally announced in February 2007, Physiomics’ In Silico simulation technology has been successfully coupled with ValiRx’s GeneICE technology to generate a cancer cell death model – the Apoptosis Model.

Physiomics Technology in support of Eli Lilly Oncology Program

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed an agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to provide in silico simulations of cancer cellular processes in support of Lilly's cancer drug discovery research.

Agreement announced between ValiRx plc and Physiomics plc

ValiRx, the cancer therapeutics company, has signed a new agreement with Physiomics to use its in silico simulations of cellular processes to reduce the development time and costs associated in identifying new therapeutic compounds for the treatment of cancers.